In Vitro |
HDAC-IN-44 (20 µg/mL; 24 h) treatment shows inhibitory effects on acute lymphoblastic leukemia (Molt 4 cells), T-cell lymphoblastic lymphoma (Sup-T1 cells), chronic myelogenous leukemia (K562 cells), gastric adenocarcinoma (AGS), prostate cancer (PC3 and LNCaP cells) and breast cancer (T47D cells) [1]. Cell Viability Assay Cell Line: Molt 4, Sup-T1, K562, AGS, PC-3, LNCaP, T47D cells[1] Concentration: 20 µg/mL Incubation Time: 24 hours Result: Exhibited IC50 values of 11, 9.1, 16.3, 7.1, 13.4, 32.7 and 9.2 μM in Molt 4, Sup-T1, K562, AGS, PC-3, LNCaP, T47D cells, respectively[1].
|